Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2013 - 2026)

Travere Therapeutics' Change in Acquisitions & Divestments history runs 14 years deep, the most recent figure standing at $48.8 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 8.23% year-over-year to $48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319.2 million (up 19.06% YoY) and the FY2025 annual result came in at $323.6 million, down 0.84% from the prior year.
• Change in Acquisitions & Divestments was $48.8 million for Q1 2026 at Travere Therapeutics, down from $82.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $152.6 million in Q2 2022 and bottomed at $48.8 million in Q1 2026.
• A 5-year average of $83.3 million and a median of $82.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments sank 57.54% — and 2025, when it soared 96.29%.
• Travere Therapeutics' Change in Acquisitions & Divestments stood at $52.4 million in 2022, then slipped by 4.55% to $50.0 million in 2023, then gained by 10.1% to $55.0 million in 2024, then jumped by 49.72% to $82.4 million in 2025, then plunged by 40.81% to $48.8 million in 2026.
• Business Quant data shows TVTX's Change in Acquisitions & Divestments at $48.8 million in Q1 2026, $82.4 million in Q4 2025, and $106.6 million in Q3 2025.